Loading contract…
BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
One or more suppliers on this contract have also made political donations. See supplier details below.
NHS Framework Agreement, Branded Medicines for London and South of England
Offer reference number: CM/PHR/20/5598
FIND A TENDER (FTS) Reference number: FTS-002229
CM/PHR/20/5598/01 - NHS Framework for LONDON Branded Medicines - Tranche B.
Period of framework: 1 September 2021 to 31 August 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months
CM/PHR/20/5598/02 - NHS Framework for the LONDON Branded Medicines - Annual Tranche. Period of framework: 1 September 2021 to 31 August 2022 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months
CM/PHR/20/5598/03 - NHS Framework for the SOUTH of England Tranche A.
Period of Framework: 1 September 2021 to 31 August 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months
CM/PHR/20/5598/04- NHS Framework for SOUTH of England - Tranche B.
Period of framework: 1 September 2021 to 31 August 2022 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months
CM/PHR/20/5598/05 - NHS Framework for the SOUTH of England Annual Tranche.
Period of Framework: 1 September 2021 to 31 August 2022 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months
CM/PHR/20/5598/06 - NHS Framework for the Midlands & East and North of England Regions - Bevacizumab Period of Framework: 1 September 2021 to 28 February 2022 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 6 months
| Supplier | Identifier | Award Value | Cross-References |
|---|---|---|---|
| Accord-UK Ltd | 00079585 | ~£1,117,043,852 estimated from lot values | - |
| Allergan | OC400028 | ~£1,117,043,852 estimated from lot values | - |
| Amgen Ltd | 02354269 | ~£1,117,043,852 estimated from lot values | - |
| AstraZeneca | 03674842 | ~£1,117,043,852 estimated from lot values | LOBBYIST Incisive Health Ltd (6 quarters) FTI Consulting LLP (6 quarters) Teneo Strategy Limited (3 quarters) Hanover Communications International Limited (2 quarters) MHP Communications (1 quarter) |
| Aventis Pharma ltd t/a Sanofi | 01535640 | ~£1,117,043,852 estimated from lot values | DONOR£101K across 3 donations To: Pauline Latham MP, Derek Thomas, Labour Party |
| Bayer Ltd | 16954143 | ~£1,117,043,852 estimated from lot values | - |
| Biogen | 06151086 | ~£1,117,043,852 estimated from lot values | - |
| Bristol Myers Squibb | 02487574 | ~£1,117,043,852 estimated from lot values | - |
| Celltrion Healthcare United Kingdom Limited | 11685363 | ~£1,117,043,852 estimated from lot values | - |
| Chugai | - | ~£1,117,043,852 estimated from lot values | - |
| CST Pharma Limited | 04212740 | ~£1,117,043,852 estimated from lot values | - |
| Daiichi Sankyo UK Ltd | 01998736 | ~£1,117,043,852 estimated from lot values | LOBBYIST WA Communications Ltd (2 quarters) Hanover Communications International Limited (1 quarter) FORMER MP Sir Kevin Barron— Employment and earnings (former) |
| Dr.Reddy's Laboratories (UK) Limited | 01729064 | ~£1,117,043,852 estimated from lot values | - |
| Eli Lilly & Company Ltd | 00284385 | ~£1,117,043,852 estimated from lot values | DONOR£9K across 1 donation To: Conservative and Unionist Party |
| Ferring Pharmaceuticals Ltd | 01198007 | ~£1,117,043,852 estimated from lot values | DONOR£1.44M across 11 donations To: Liberal Democrats |
| Gedeon Richter UK Ltd | 04325685 | ~£1,117,043,852 estimated from lot values | - |
| Gilead Sciences Limited | 02543818 | ~£1,117,043,852 estimated from lot values | LOBBYIST Ovid Consulting Ltd (4 quarters) Portland PR Limited (1 quarter) WA Communications Ltd (1 quarter) |
| Ipsen | 06751069 | ~£1,117,043,852 estimated from lot values | LOBBYIST Burkitt Communications Ltd (2 quarters) WA Communications Ltd (1 quarter) |
| Janssen-Cilag Ltd | 01027904 | ~£1,117,043,852 estimated from lot values | LOBBYIST Ovid Consulting Ltd (4 quarters) |
| Merck Serono Limited | 00990823 | ~£1,117,043,852 estimated from lot values | MP LINK Munira Wilson— Employment and earnings |
| Merck Sharpe & Dohme (UK) Limited | - | ~£1,117,043,852 estimated from lot values | - |
| Merz | - | ~£1,117,043,852 estimated from lot values | - |
| Morningside Pharmaeuticals | - | ~£1,117,043,852 estimated from lot values | - |
| Mylan | 05460854 | ~£1,117,043,852 estimated from lot values | - |
| Napp Pharmaceuticals Ltd | 03690299 | ~£1,117,043,852 estimated from lot values | - |
| Novo Nordisk | 01118740 | ~£1,117,043,852 estimated from lot values | LOBBYIST WA Communications Ltd (7 quarters) Hanover Communications International Limited (2 quarters) MHP Communications (1 quarter) |
| Organon Pharmaceuticals UK Ltd | - | ~£1,117,043,852 estimated from lot values | - |
| Pfizer Ltd | 00526209 | ~£1,117,043,852 estimated from lot values | DONOR£41K across 4 donations To: Progressive Britain Ltd (formally Progress Ltd) LOBBYIST Portland PR Limited (20 quarters) Ovid Consulting Ltd (3 quarters) Hanover Communications International Limited (3 quarters) Incisive Health Ltd (1 quarter) MHP Communications (1 quarter) FORMER MP John Austin— Gifts, benefits and hospitality from UK sources (former) |
| Pharmacosmos UK Ltd | 03104505 | ~£1,117,043,852 estimated from lot values | - |
| Profile Pharma Ltd | 04005203 | ~£1,117,043,852 estimated from lot values | - |
| Roche Products Ltd | 00100674 | ~£1,117,043,852 estimated from lot values | LOBBYIST M&F Health (5 quarters) Ovid Consulting Ltd (2 quarters) |
| Sandoz Ltd | 01547204 | ~£1,117,043,852 estimated from lot values | - |
| Sobi (Swedish Orphan Biovitrum Ltd) | - | ~£1,117,043,852 estimated from lot values | - |
| Takeda UK Ltd | 03362860 | ~£1,117,043,852 estimated from lot values | LOBBYIST Hill & Knowlton Limited (3 quarters) Hanover Communications International Limited (2 quarters) MHP Communications (2 quarters) Burkitt Communications Ltd (1 quarter) Incisive Health Ltd (1 quarter) FORMER MP Sir Kevin Barron— Employment and earnings (former) |
| Techdow Pharma England Ltd | 10513412 | ~£1,117,043,852 estimated from lot values | - |
| Tetris Pharma Lts | - | ~£1,117,043,852 estimated from lot values | - |
| Teva UK Limited | 00302461 | ~£1,117,043,852 estimated from lot values | - |
| Thornton and Ross Ltd | 00185947 | ~£1,117,043,852 estimated from lot values | - |
| UCB | - | ~£1,117,043,852 estimated from lot values | - |
| UL Global Pharma | - | ~£1,117,043,852 estimated from lot values | - |
| Vifor Pharma UK Ltd | 06514784 | ~£1,117,043,852 estimated from lot values | - |
| Zentiva Pharma UK Ltd | 02158996 | ~£1,117,043,852 estimated from lot values | - |
Government spending data: These suppliers have received £932,268,246 in 6,173 payments (over £25k) from UK Health Security Agency, Department of Health and Social Care, Manchester University NHS Foundation Trust, NHS England, Royal Cornwall Hospitals NHS Trust and 21 more public bodies (2010-04-28 to 2026-03-31).